<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842254</url>
  </required_header>
  <id_info>
    <org_study_id>STU00206077</org_study_id>
    <nct_id>NCT03842254</nct_id>
  </id_info>
  <brief_title>Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease</brief_title>
  <official_title>Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Sinai Hospital, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of erythropoietin on the number and function of regulatory T&#xD;
      cells in adults with autoimmune hepatitis. Participants will receive a single dose of&#xD;
      erythropoietin, and then the investigators will collect blood at different time points for&#xD;
      analysis of regulatory T cell number and function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is data from the laboratory that erythropoietin helps stimulate regulatory T cells, a&#xD;
      type of immune cell which is thought to combat autoimmunity, but this study will look at&#xD;
      whether it does the same thing in adults with autoimmune hepatitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Actual">February 18, 2021</completion_date>
  <primary_completion_date type="Actual">February 18, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of regulatory T cells</measure>
    <time_frame>At time of enrollment, then at 2 weeks, 4 weeks, and 12 weeks.</time_frame>
    <description>Calculated relative to baseline collected at time of enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of effector T cells after a single dose of erythropoietin</measure>
    <time_frame>At time of enrollment, then at 2 weeks, 4 weeks, and 12 weeks.</time_frame>
    <description>Calculated relative to baseline collected at time of enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cytokine production by the T cells in response to ex vivo stimulation</measure>
    <time_frame>At time of enrollment, then at 2 weeks, 4 weeks, and 12 weeks.</time_frame>
    <description>Calculated relative to baseline collected at time of enrollment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of erythropoietin 10,000 units to be administered subcutaneously at time of enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Subcutaneous injection of erythropoietin 10,000 units</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of autoimmune liver diseases (autoimmune hepatitis, autoimmune&#xD;
             cholangiopathy, or primary biliary cirrhosis or primary sclerosing cholangitis with&#xD;
             hepatic autoimmune liver disease or overlap syndrome) confirmed on liver biopsy&#xD;
&#xD;
          -  Use of immunosuppressive therapy (prednisone, azathioprine, 6-mercaptopurine,&#xD;
             mycophenolate mofetil) for the treatment of the autoimmune liver disease&#xD;
&#xD;
          -  Stable immunosuppression regimen at least 6 months prior to enrollment&#xD;
&#xD;
          -  Ability to provide verbal and written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of decompensated cirrhosis (defined by presence of ascites, varices,&#xD;
             encephalopathy)&#xD;
&#xD;
          -  Hemoglobin above average normal value (15.7 g/dL in men, 13.8 g/dL in women)&#xD;
&#xD;
          -  Alanine aminotransferase greater than 2 times upper limit of normal (33 IU/L in men&#xD;
             and 25 IU/L in women)&#xD;
&#xD;
          -  Uncontrolled hypertension with systolic blood pressure greater than or equal to 160 or&#xD;
             diastolic blood pressure greater than or equal to 100&#xD;
&#xD;
          -  End-stage renal disease on hemodialysis&#xD;
&#xD;
          -  History of venous thromboembolism including deep vein thromboses or pulmonary emboli&#xD;
&#xD;
          -  History of stroke&#xD;
&#xD;
          -  History of heart failure&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  History of significant cardiovascular disease including a history of myocardial&#xD;
             infarction&#xD;
&#xD;
          -  Active malignancy (untreated or undergoing therapy)&#xD;
&#xD;
          -  History of pure red cell aplasia&#xD;
&#xD;
          -  History of intolerance or allergy to erythropoietin&#xD;
&#xD;
          -  Known hypersensitivity to mammalian cell-derived products&#xD;
&#xD;
          -  Known hypersensitivity to human albumin&#xD;
&#xD;
          -  Presence of vascular access&#xD;
&#xD;
          -  Prior recipient of erythropoietin within 12 weeks of the study&#xD;
&#xD;
          -  Patient unable to provide consent including infants, children, teenagers, prisoners,&#xD;
             cognitively impaired adults&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Josh Levitsky</investigator_full_name>
    <investigator_title>Professor of Medicine and Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

